{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:24:03Z","timestamp":1789453443536,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Research on Metabolic Associated Fatty Liver Disease (MAFLD) is still in its early stages, with few studies available to identify and predict effective indicators of this disease. On the other hand, early diagnosis and intervention are crucial to reduce the burden of MAFLD. Therefore, the aim of this research was to investigate the effectiveness of eleven anthropometric indices and their appropriate cut-off values as a non-invasive method to predict and diagnose MAFLD in the Iranian population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional study, we analyzed baseline data from the Hoveyzeh Cohort Study, a prospective population-based study conducted in Iran that enrolled a total of 7836 subjects aged 35 to 70 years from May 2016 through August 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The optimal cut-off values of anthropometric indices for predicting MAFLD risk were determined for waist circumference(WC) (102.25\u00a0cm for males and 101.45\u00a0cm for females), body mass index (BMI) (27.80\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      for males and 28.75\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      for females), waist-to-hip ratio (WHR) (0.96 for both males and females), waist-to-height ratio (WHtR) (0.56 for males and 0.63 for females), body adiposity index (BAI) (23.24 for males and 32.97 for females), visceral adiposity index (VAI) (1.64 for males and 1.88 for females), weight-adjusted waist index (WWI) (10.63 for males and 11.71 for females), conicity index (CI) (1.29 for males and 1.36 for females), body roundness index (BRI) (4.52 for males and 6.45 for females), relative fat mass (RFM) (28.18 for males and 44.91 for females) and abdominal volume index (AVI) (18.85 for males and for 21.37 females). VAI in males (sensitivity: 77%, specificity: 60%, Youden\u2019s Index: 0.37) and RFM in females (sensitivity: 76%, specificity: 59%, Youden\u2019s Index: 0.35) were found to have higher sensitivity and specificity compared to other anthropometric indices. Furthermore, anthropometric indices demonstrated statistically significant correlations with various hepatic and cardiometabolic indices. Among these, the strongest positive correlations were observed between WC, BMI, BAI, BRI, and AVI with the Hepatic Steatosis Index (HSI), TyG-BMI, and TyG-WC, as well as between VAI and the Atherogenic Index of Plasma (AIP), Lipid Accumulation Product (LAP), Cardiometabolic Index (CMI), and the Triglyceride and Glucose (TyG) Index.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anthropometric indices are effective in predicting MAFLD risk among Iranian adults, with WWI, VAI, and RFM identified as the strongest predictors. The proposed cutoff values could serve as a straightforward and non-invasive methods for the early diagnosis of MAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-024-01615-3","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T09:03:50Z","timestamp":1717491830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Assessment of the appropriate cutoff points for anthropometric indices and their relationship with cardio-metabolic indices to predict the risk of metabolic associated fatty liver disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Seyed Ahmad","family":"Hosseini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meysam","family":"Alipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sarvandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Haghighat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Bazyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-4629","authenticated-orcid":false,"given":"Ladan","family":"Aghakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"issue":"11","key":"1615_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi T, Eslam M, Kawaguchi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115\u201328.","journal-title":"Hepatol Res"},{"issue":"6","key":"1615_CR2","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1002\/jcsm.13099","volume":"13","author":"JY Seo","year":"2022","unstructured":"Seo JY, Cho EJ, Kim MJ, et al. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population. J Cachexia Sarcopenia Muscle. 2022;13(6):2953\u201360.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"1615_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13098-022-00887-w","volume":"14","author":"T Tsutsumi","year":"2022","unstructured":"Tsutsumi T, Nakano D, Kawaguchi M, et al. MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men. Diabetol Metab Syndr. 2022;14(1):115.","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"1615_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","volume":"10","author":"E Kaya","year":"2022","unstructured":"Kaya E, Yilmaz Y. Metabolic-associated fatty liver Disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10(2):329\u201338.","journal-title":"J Clin Transl Hepatol"},{"key":"1615_CR5","doi-asserted-by":"crossref","unstructured":"Dro\u017cd\u017c K, Nabrdalik K, Hajzler W et al. Metabolic-Associated fatty liver Disease (MAFLD), diabetes, and Cardiovascular Disease: associations with Fructose Metabolism and Gut Microbiota. Nutrients. 2021;14(1):103.","DOI":"10.3390\/nu14010103"},{"key":"1615_CR6","doi-asserted-by":"crossref","unstructured":"Duan S, Yang D, Xia H et al. Cardiometabolic index: a new predictor for metabolic associated fatty liver disease in Chinese adults. Front Endocrinol. 2022;13:1004855.","DOI":"10.3389\/fendo.2022.1004855"},{"issue":"1","key":"1615_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"key":"1615_CR8","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S383907","volume-title":"Association Between Triglyceride-Glucose Index and Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Cohort Study","author":"R Zhang","year":"2022","unstructured":"Zhang R, Guan Q, Zhang M, et al. Association between triglyceride-glucose Index and Risk of Metabolic Dysfunction-Associated fatty liver disease: a Cohort Study. Diabetes Metab Syndr Obes. 2022;15:3167-179."},{"issue":"2","key":"1615_CR9","first-page":"37","volume":"2","author":"Y Yilmaz","year":"2021","unstructured":"Yilmaz Y, Yilmaz N, Ates F, et al. The prevalence of metabolic-associated fatty liver disease in the Turkish population: a multicenter study. Hepatol Forum. 2021;2(2):37\u201342.","journal-title":"Hepatol Forum"},{"issue":"3","key":"1615_CR10","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/j.cgh.2021.02.030","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu J, Ayada I, Zhang X, et al. Estimating Global Prevalence of Metabolic Dysfunction-Associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20(3):e573\u201382.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1615_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-021-01568-9","volume":"20","author":"J Cai","year":"2021","unstructured":"Cai J, Lin C, Lai S, et al. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the western Chinese male population. Lipids Health Dis. 2021;20(1):1\u201312.","journal-title":"Lipids Health Dis"},{"issue":"Suppl1","key":"1615_CR12","first-page":"S102","volume":"14","author":"E Taheri","year":"2021","unstructured":"Taheri E, Moslem A, Mousavi-Jarrahi A, et al. Predictors of metabolic-associated fatty liver disease (MAFLD) in adults: a population-based study in northeastern Iran. Gastroenterol Hepatol Bed Bench. 2021;14(Suppl1):S102\u201311.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"3","key":"1615_CR13","doi-asserted-by":"publisher","first-page":"101807","DOI":"10.1016\/j.clinre.2021.101807","volume":"46","author":"A Cordeiro","year":"2022","unstructured":"Cordeiro A, Ribamar A, Ramalho A. Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19. Clin Res Hepatol Gastroenterol. 2022;46(3):101807.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"1615_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.15537\/smj.2017.4.18758","volume":"38","author":"MM Abulmeaty","year":"2017","unstructured":"Abulmeaty MM, Almajwal AM, Almadani NK, et al. Anthropometric and central obesity indices as predictors of long-term cardiometabolic risk among Saudi young and middle-aged men and women. Saudi Med J. 2017;38(4):372\u201380.","journal-title":"Saudi Med J"},{"issue":"6\u20138","key":"1615_CR15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1080\/03014460.2018.1562568","volume":"45","author":"F Lajeunesse-Trempe","year":"2018","unstructured":"Lajeunesse-Trempe F, Dufour R, du Souich P, et al. Anthropometric measures and their association with risk factors for cardio-metabolic diseases in Kenyan adults. Ann Hum Biol. 2018;45(6\u20138):486\u201395.","journal-title":"Ann Hum Biol"},{"key":"1615_CR16","doi-asserted-by":"crossref","unstructured":"El Hadi H, Di Vincenzo A, Vettor R et al. Cardio-metabolic disorders in non-alcoholic fatty liver disease. Int J Mol Sci. 2019;20(9):2215.","DOI":"10.3390\/ijms20092215"},{"issue":"1","key":"1615_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-0032-1306423","volume":"32","author":"H Chatrath","year":"2012","unstructured":"Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32(1):22\u20139.","journal-title":"Semin Liver Dis"},{"issue":"6","key":"1615_CR18","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","volume":"75","author":"D Kim","year":"2021","unstructured":"Kim D, Konyn P, Sandhu KK, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284\u201391.","journal-title":"J Hepatol"},{"key":"1615_CR19","first-page":"141","volume":"34","author":"B Cheraghian","year":"2020","unstructured":"Cheraghian B, Hashemi S, Hosseini J. Cohort profile: the Hoveyzeh Cohort Study (HCS): a prospective population-based study on non-communicable diseases in an arab community of Southwest Iran. Med J Islam Repub Iran. 2020;34:141.","journal-title":"Med J Islam Repub Iran"},{"issue":"8","key":"1615_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.5152\/tjg.2021.20512","volume":"32","author":"HT Kani","year":"2021","unstructured":"Kani HT, Demirtas CO, Keklikkiran C, et al. Evaluation of the impact of metabolic syndrome on Fibrosis in Metabolic Dysfunction-Associated fatty liver disease. Turk J Gastroenterol. 2021;32(8):661\u20136.","journal-title":"Turk J Gastroenterol"},{"key":"1615_CR21","doi-asserted-by":"crossref","unstructured":"Shen Y, Wu Y, Fu M. al. Association between weight-adjusted-waist index with hepatic steatosis and liver fibrosis: a nationally representative cross-sectional study from NHANES 2017 to 2020. Front Endocrinol. 2023;14:1159055.","DOI":"10.3389\/fendo.2023.1159055"},{"issue":"1","key":"1615_CR22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s13018-023-03776-8","volume":"18","author":"J Tao","year":"2023","unstructured":"Tao J, Zhang Y, Tan C, et al. Associations between weight-adjusted waist index and fractures: a population-based study. J Orthop Surg Res. 2023;18(1):290.","journal-title":"J Orthop Surg Res"},{"key":"1615_CR23","doi-asserted-by":"publisher","first-page":"1035418","DOI":"10.3389\/fendo.2022.1035418","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Duan S, Wang C, et al. Optimum non-invasive predictive indicators for metabolic dysfunction-associated fatty liver disease and its subgroups in the Chinese population: a retrospective case-control study. Front Endocrinol (Lausanne). 2022;13:1035418.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1615_CR24","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1186\/s12889-023-15365-9","volume":"23","author":"Z Yang","year":"2023","unstructured":"Yang Z, Yu B, Wang Z, et al. Comparison of the prognostic value of a comprehensive set of predictors in identifying risk of metabolic-associated fatty liver disease among employed adults. BMC Public Health. 2023;23(1):584.","journal-title":"BMC Public Health"},{"issue":"3","key":"1615_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.clinre.2019.04.002","volume":"44","author":"T Okamura","year":"2020","unstructured":"Okamura T, Hashimoto Y, Hamaguchi M, et al. The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: a population-based longitudinal study. Clin Res Hepatol Gastroenterol. 2020;44(3):375\u201383.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1615_CR26","doi-asserted-by":"crossref","unstructured":"Ismaiel A, Jaaouani A, Leucuta DC et al. The visceral Adiposity Index in non-alcoholic fatty liver disease and liver fibrosis-systematic review and Meta-analysis. Biomedicines. 2021;9(12):1890.","DOI":"10.3390\/biomedicines9121890"},{"issue":"1","key":"1615_CR27","doi-asserted-by":"publisher","first-page":"10980","DOI":"10.1038\/s41598-018-29362-1","volume":"8","author":"OO Woolcott","year":"2018","unstructured":"Woolcott OO, Bergman RN. Relative fat mass (RFM) as a new estimator of whole-body fat percentage a cross-sectional study in American adult individuals. Sci Rep. 2018;8(1):10980.","journal-title":"Sci Rep"},{"issue":"2","key":"1615_CR28","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s11695-019-04213-8","volume":"30","author":"MV Machado","year":"2020","unstructured":"Machado MV, Policarpo S, Coutinho J, et al. What is the role of the New Index relative Fat Mass (RFM) in the Assessment of nonalcoholic fatty liver Disease (NAFLD)? Obesity surgery. 2020;30(2):560\u20138.","journal-title":"Obesity surgery"},{"issue":"4","key":"1615_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5491\/SHAW.2012.3.4.287","volume":"3","author":"N Abe","year":"2012","unstructured":"Abe N, Honda S, Jahng D. Evaluation of Waist circumference cut-off values as a marker for fatty liver among Japanese workers. Saf Health Work. 2012;3(4):287\u201393.","journal-title":"Saf Health Work"},{"key":"1615_CR30","doi-asserted-by":"crossref","unstructured":"Lee JH, Jeon S, Lee HS et al. Cutoff points of Waist circumference for Predicting Incident non-alcoholic fatty liver disease in Middle-aged and older Korean adults. Nutrients. 2022;14(14):2994.","DOI":"10.3390\/nu14142994"},{"issue":"8","key":"1615_CR31","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.1478-3231.2010.02300.x","volume":"30","author":"HJ Yoo","year":"2010","unstructured":"Yoo HJ, Park MS, Lee CH, et al. Cutoff points of abdominal obesity indices in screening for non-alcoholic fatty liver disease in asians. Liver Int. 2010;30(8):1189\u201396.","journal-title":"Liver Int"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01615-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-024-01615-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01615-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T09:06:06Z","timestamp":1717491966000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-024-01615-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1186\/s12902-024-01615-3","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"6 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was in accordance with the Helsinki Declarations and approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Science (IR.AJUMS.REC.1400.601).All subjects gave informed consent before entering the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}